Group 1 - Oricell Therapeutics and Umoja Biopharma announced a strategic collaboration to develop innovative in vivo CAR-T therapies for various indications, aiming to provide efficient and accessible treatment options for patients globally [1][2] - Umoja's VivoVec™ platform enables the direct generation of CAR-T cells within patients, enhancing the convenience and effectiveness of treatment [1][2] - Oricell contributes its expertise in antibody discovery and CAR structure design, which has demonstrated best-in-class efficacy and safety in clinical data for products Ori-C101 and OriCAR-017 [1][3] Group 2 - Umoja Biopharma focuses on developing innovative in vivo cell therapies to improve the accessibility and effectiveness of CAR-T therapies in oncology and autoimmune diseases [2] - The company operates an advanced lentiviral vector development and production facility in Colorado, ensuring high-quality and safe products through GMP-compliant manufacturing processes [2] - Oricell is dedicated to becoming a leading innovator in tumor immunotherapy, addressing unmet clinical needs in oncology and immunology through its proprietary platforms and product pipelines [3]
原启生物与Umoja Biopharma达成战略合作 携手开发下一代细胞疗法
Sou Hu Wang·2025-05-08 08:35